bioMérieux Receives CE Mark for Two New Rapid PCR Tests
bioMérieux has announced the acquisition of the CE mark under the IVDR directive for two diagnostic tests for respiratory and pharyngeal infections. These multiplex PCR tests, compatible with bedside use, are now authorized in Europe for deployment outside of traditional laboratories.
The BIOFIRE® SPOTFIRE® Respiratory/Sore Throat plus (R/STplus) Panel and BIOFIRE® SPOTFIRE® R/STplus Panel Mini have received the CE mark under the IVDR, including the 'Near-Patient Testing' classification allowing use at the point of care. These multiplex PCR tests can simultaneously detect pathogens responsible for respiratory infections and sore throats in about 15 minutes. The standard panel detects 15 pathogens, while the Mini panel identifies 6, including human rhinovirus/enterovirus, Streptococcus A, influenza A/B viruses, RSV, and SARS-CoV-2. Samples can be taken using nasopharyngeal, oropharyngeal swabs, or, for the Mini panel, anterior nasal swabs.
Enhancement of Respiratory Diagnostic Offerings
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The BIOFIRE® SPOTFIRE® R/STplus Panel replaces the previous version marketed with the CE mark under the IVDD directive. bioMérieux is simultaneously introducing the R/STplus Panel Mini, enhancing its respiratory diagnostic offerings in Europe. Both tests will be available in the second quarter of 2026 in countries recognizing the CE mark, and will then be deployed in other regions outside the United States according to local regulations.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 1 965 millions d'euros
Quarterly revenue: 1 965 millions d'euros
Revenue growth: -3,9 %
EBITDA: 440,3 millions d'euros
EBITDA margin: 22,4 %
Net income: 226,1 millions d'euros
Free cash flow: 299 millions d'euros
-235,9 millions d'euros
Guidance from the release
confirme ses perspectives pour 2026 : croissance organique du chiffre d'affaires comprise entre +3% et +5%, CEBIT croissance comprise entre 0% et +10%
Risks mentioned
Épidémiologie respiratoire plus faible : recul organique de 17 % des panels respiratoires BIOFIRE®
Effet de change défavorable de 35 M€ sur le ROCC du premier semestre 2026
Environnement géopolitique et macroéconomique dégradé depuis 2024
Opportunities identified
Croissance organique de 6 % des quatre moteurs de croissance du plan GO•28
Dépôt auprès de la FDA du panel SPOTFIRE® Vaginitis
Obtention du marquage CE du premier test SPINCHIP®
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
